The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 21, 2006
Filed:
Apr. 21, 2004
Karl-heinz Altmann, Reinach, CH;
Guido Bold, Gipf-Oberfrick, CH;
Pascal Furet, Thann, FR;
Paul William Manley, Arlesheim, CH;
Jeanette Marjorie Wood, Biel Benken, CH;
Stefano Ferrari, Muttenz, CH;
Francesco Hofmann, Bottmingen, CH;
Jürgen Mestan, Denzlingen, DE;
Andreas Huth, Berlin, DE;
Martin Krüger, Berlin, DE;
Dieter Seidelmann, Berlin, DE;
Andreas Menrad, Oranienburg, DE;
Martin Haberey, Berlin, DE;
Karl-heinz Thierauch, Berlin, DE;
Karl-Heinz Altmann, Reinach, CH;
Guido Bold, Gipf-Oberfrick, CH;
Pascal Furet, Thann, FR;
Paul William Manley, Arlesheim, CH;
Jeanette Marjorie Wood, Biel Benken, CH;
Stefano Ferrari, Muttenz, CH;
Francesco Hofmann, Bottmingen, CH;
Jürgen Mestan, Denzlingen, DE;
Andreas Huth, Berlin, DE;
Martin Krüger, Berlin, DE;
Dieter Seidelmann, Berlin, DE;
Andreas Menrad, Oranienburg, DE;
Martin Haberey, Berlin, DE;
Karl-Heinz Thierauch, Berlin, DE;
Novartis AG, Basel, CH;
Schering Aktiengesellschaft, Berlin, DE;
Abstract
Described are compunds of formula (I), wherein W is O or S; X is NR; Y is CRR—(CH)n wherein Rand Rare independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO; Ris aryl; Ris a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that Rcannot represent 2-phthalimidyl, and in case of Y=SOcannot represent 2,1,3-benzothiadiazol-4-yl; any of R, R, Rand R, independently of the other, is H or a substituent other than hydrogen; and Rand R, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.